INTRODUCTION .......................................................................................................................................................229 Clinical Leishmaniasis ...........................................................................................................................................229 Self-limiting cutaneous and visceral leishmaniasis ...............

INTRODUCTION .......................................................................................................................................................229 Clinical Leishmaniasis ...........................................................................................................................................229 Self-limiting cutaneous and visceral leishmaniasis ...............

Leishmaniasis is caused by the infection of haemoparasite „Leishmaniadonovani’. Clinically it can present as Cutaneous Leishmaniasis (CL), Mucocutaneous Leishmaniasis (MCL) and Visceral Leishmaniasis (VL). In India it is a major health problem in the North & Central regions of India and is infrequently reported from western India. However, we encountered two clinically suspected cases of Leishm...

Leishmaniasis is a disease caused by protozoa of the genus Leishmania, and visceral leishmaniasis is a form in which the inner organs are affected. Since knowledge about immunity in experimental visceral leishmaniasis is poor, we present here a review on immunity and immunosuppression in experimental visceral leishmaniasis in mouse and hamster models. We show the complexity of the mechanisms in...

A PCR assay amplifying a repeated sequence from the Leishmania infantum genome was compared with direct examination of bone marrow aspirate, myeloculture, and serology for the diagnosis of visceral leishmaniasis in immunocompromised patients. Of 73 patients living in an area endemic for leishmaniasis and where visceral leishmaniasis was suspected by physicians, only 10 had an indisputable diagn...

UNLABELLED Leishmania donovani is an intracellular protozoan parasite that causes leishmaniasis, which can range from a self-healing cutaneous disease to a fatal visceral disease depending on the infecting species. Miltefosine is currently the latest and only oral antileishmanial that came out of drug discovery pipelines in the past few decades, but recent reports indicate a significant decline...

Visceral leishmaniasis is a serious public health problem. Leishmania infantum is one of its causative agents. LCR1 is an immunogen from L. infantum. Antibodies against this protein have been detected in visceral leishmaniasis patients. The aim of this study was to define the antibody and cellular immune responses against LCR1 in Iranian visceral leishmaniasis patients and recovered individuals...

BACKGROUND Leishmaniasis is endemic in 98 countries with an estimated 350 million people at risk and approximately 2 million cases annually. Brazil is one of the most severely affected countries. METHODOLOGY We applied Bayesian geostatistical negative binomial models to analyze reported incidence data of cutaneous and visceral leishmaniasis in Brazil covering a 10-year period (2001-2010). Par...

INTRODUCTION The diseases caused by Leishmania are spread worldwide and represent a significant public health problem. OBJECTIVE The aim of this study was to present the results of epidemiological surveillance of leishmaniasis in humans in Montenegro in the period from 1992 to 2013. METHODS The study was planned and realized as a descriptive epidemiological study.The sample included patient...